ORYN Stock Chart & Stats
$48.59
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$48.59 - $48.59
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$4.88B
Enterprise Value$198.92
Total Cash (Recent Filing)$22.12M
Total Debt (Recent Filing)$7.10M
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Jul 29, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding84,332,150
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio2.31
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-95.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Oryzon Genomics SA News
ORYN FAQ
What was Oryzon Genomics’s price range in the past 12 months?
Oryzon Genomics lowest stock price was $48.59 and its highest was $48.59 in the past 12 months.
What is Oryzon Genomics’s market cap?
Oryzon Genomics’s market cap is $4.88B.
When is Oryzon Genomics’s upcoming earnings report date?
Oryzon Genomics’s upcoming earnings report date is Jul 29, 2026 which is in 4 days.
How were Oryzon Genomics’s earnings last quarter?
Oryzon Genomics released its earnings results on May 14, 2026. The company reported -$0.338 earnings per share for the quarter, the consensus estimate of -$0.338 by $0.
Is Oryzon Genomics overvalued?
According to Wall Street analysts Oryzon Genomics’s price is currently Undervalued.
Does Oryzon Genomics pay dividends?
Oryzon Genomics does not currently pay dividends.
What is Oryzon Genomics’s EPS estimate?
Oryzon Genomics’s EPS estimate is -1.11.
How many shares outstanding does Oryzon Genomics have?
Oryzon Genomics has 84,332,150 shares outstanding.
What happened to Oryzon Genomics’s price movement after its last earnings report?
Oryzon Genomics reported an EPS of -$0.338 in its last earnings report, expectations of -$0.338. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Oryzon Genomics?
Currently, no hedge funds are holding shares in MX:ORYN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oryzon Genomics
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.